A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges
Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLCγ1, PI3K, and STATs. In the last ten years, it has become clear that FGF signalling i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Urology |
| Online Access: | http://dx.doi.org/10.1155/2012/429213 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560629922136064 |
|---|---|
| author | Erica di Martino Darren C. Tomlinson Margaret A. Knowles |
| author_facet | Erica di Martino Darren C. Tomlinson Margaret A. Knowles |
| author_sort | Erica di Martino |
| collection | DOAJ |
| description | Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLCγ1, PI3K, and STATs. In the last ten years, it has become clear that FGF signalling is altered in a high proportion of bladder tumours. Activating mutations and/or overexpression of FGFR3 are common in urothelial tumours with low malignant potential and low-stage and -grade urothelial carcinomas (UCs) and are associated with a lower risk of progression and better survival in some subgroups. FGFR1 is not mutated in UC, but overexpression is frequent in all grades and stages and recent data indicate a role in urothelial epithelial-mesenchymal transition. In vitro and in vivo studies have shown that FGFR inhibition has cytotoxic and/or cytostatic effects in FGFR-dependent bladder cancer cells and FGFR-targeted agents are currently being investigated in clinical studies for the treatment of UC. Urine-based tests detecting common FGFR3 mutations are also under development for surveillance of low-grade and -stage tumours and for general population screening. Overall, FGFRs hold promise as therapeutic targets, diagnostic and prognostic markers, and screening tools for early detection and clinical management of UC. |
| format | Article |
| id | doaj-art-dbc870bde6fd4e349e88de0c751985d9 |
| institution | Kabale University |
| issn | 1687-6369 1687-6377 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Urology |
| spelling | doaj-art-dbc870bde6fd4e349e88de0c751985d92025-02-03T01:27:11ZengWileyAdvances in Urology1687-63691687-63772012-01-01201210.1155/2012/429213429213A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future ChallengesErica di Martino0Darren C. Tomlinson1Margaret A. Knowles2Section of Experimental Oncology, Leeds Institute of Molecular Medicine, St James’s University Hospital, Leeds LS9 7TF, UKInstitute of Molecular and Cellular Biology, University of Leeds, Leeds LS2 9JT, UKSection of Experimental Oncology, Leeds Institute of Molecular Medicine, St James’s University Hospital, Leeds LS9 7TF, UKFibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFRs) and activating downstream signalling pathways, including RAS/MAPK, PLCγ1, PI3K, and STATs. In the last ten years, it has become clear that FGF signalling is altered in a high proportion of bladder tumours. Activating mutations and/or overexpression of FGFR3 are common in urothelial tumours with low malignant potential and low-stage and -grade urothelial carcinomas (UCs) and are associated with a lower risk of progression and better survival in some subgroups. FGFR1 is not mutated in UC, but overexpression is frequent in all grades and stages and recent data indicate a role in urothelial epithelial-mesenchymal transition. In vitro and in vivo studies have shown that FGFR inhibition has cytotoxic and/or cytostatic effects in FGFR-dependent bladder cancer cells and FGFR-targeted agents are currently being investigated in clinical studies for the treatment of UC. Urine-based tests detecting common FGFR3 mutations are also under development for surveillance of low-grade and -stage tumours and for general population screening. Overall, FGFRs hold promise as therapeutic targets, diagnostic and prognostic markers, and screening tools for early detection and clinical management of UC.http://dx.doi.org/10.1155/2012/429213 |
| spellingShingle | Erica di Martino Darren C. Tomlinson Margaret A. Knowles A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges Advances in Urology |
| title | A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges |
| title_full | A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges |
| title_fullStr | A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges |
| title_full_unstemmed | A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges |
| title_short | A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges |
| title_sort | decade of fgf receptor research in bladder cancer past present and future challenges |
| url | http://dx.doi.org/10.1155/2012/429213 |
| work_keys_str_mv | AT ericadimartino adecadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges AT darrenctomlinson adecadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges AT margaretaknowles adecadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges AT ericadimartino decadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges AT darrenctomlinson decadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges AT margaretaknowles decadeoffgfreceptorresearchinbladdercancerpastpresentandfuturechallenges |